ADU-1805
- Generic Name
- ADU-1805
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Refractory CancerMetastatic Solid TumorSolid Tumor, Adult
- Interventions
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Sairopa B.V.
- Target Recruit Count
- 90
- Registration Number
- NCT05856981
- Locations
- 🇺🇸
Henry Ford Cancer Institute, Detroit, Michigan, United States
🇺🇸Washington University Medical Campus, St. Louis, Missouri, United States
🇺🇸Virginia Cancer Specialists, FairFax, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath